Tris Pharma Appoints Franchesca Fowler to Executive Team

Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, has appointed Franchesca Fowler, JD, as chief compliance officer and vice president, general counsel. Ms. Fowler will oversee all legal matters within the company, including legal compliance, IP management, litigation and more.
 
Ms. Fowler brings 15 years of experience, most recently serving as the head of legal and compliance, as well as the global associate general counsel, for Demant, a global medical device company based in Copenhagen. At Demant, she spearheaded legal and compliance efforts for the company’s subsidiaries in the U.S. spanning retail, manufacturing and diagnostics, as well as fostered a culture of compliance and authenticity within its internal organizations. Prior to Demant, Ms. Fowler supported the GE life science business as a legal deal support leader. 
 
“I am pleased to welcome Franchesca to the executive team, and I am confident that she will be a tremendous asset to the organization as we continue to serve individuals with ADHD through our portfolio of marketed products and advance our robust pipeline of investigational therapies for the treatment of ADHD, pain, addiction and neurological disorders,” said Ketan Mehta, founder and CEO at Tris Pharma.”